Table 4.
Variation in medication use by subjects over the course of the study
| Patients Chronically Treated at Baseline (%) | Patient numbers (% of reported data) | ||||
|---|---|---|---|---|---|
| Base-6 mo | Base—12 mo | Base—18 mo | Base—24 mo | ||
| ACE-I/ARB | 112 (84) | ||||
| Added | 3 (3) | 4 (4) | 6 (7) | 6 (8) | |
| Stopped | 6 (6) | 7 (7) | 7 (8) | 7 (9) | |
| No change or not used | 97 (92) | 93 (89) | 80 (86) | 62 (83) | |
| # of patients with data | 134 | 106 | 105 | 95 | 77 |
| Beta-blocker | 127 (95) | ||||
| Added | 1 (1) | (2) | 2 (2) | 2 (3) | |
| Stopped | 3 (3) | 3 (2) | 4 (4) | 4 (5) | |
| No change or not used | 102 (96) | 99 (95) | 87 (94) | 69 (92) | |
| Aldosterone antagonist | 87 (65) | ||||
| Added | 7 (7) | 9 (9) | 7 (8) | 6 (8) | |
| Stopped | 8 (7) | 12 (11) | 11 (12) | 7 (9) | |
| No change or not used | 91 (86) | 83 (80) | 75 (80) | 62 (83) | |
The number of patients with reported data at each timepoint is shown (# of patients with data). The number of patients where drug was added, stopped, or unchanged/not used is shown in columns on the right. There was no difference in medication use from baseline to any of three time points (6, 12, 18, or 24 months). This was true for all three classes of heart failure medications (ACE-I/ARB, beta-blockers, aldosterone antagonists)